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Torasemide is a loop diuretic licensed in dogs for cardiogenic pulmonary oedema. The
aim of this pharmacokinetic-pharmacodynamic (PK/PD) study was to define an optimally
effective dosage regimen based on preclinical data. In a first study, 5 dogs received
once-daily oral torasemide (0, 0.1, 0.2, 0.4, 0.8 mg/kg/day) for 14 days. A second study
compared once-daily oral torasemide (0, 0.1, 0.2, 0.3, 0.4 mg/kg/day) to twice-daily
furosemide (1, 2, 4, 8 mg/kg/day). For all doses of the second study, 11 dogs received
a first day of treatment, followed by a 3 day washout and resumed daily treatment for
10 days (until Day 14). Blood and urine were collected to measure urinary torasemide
excretion and plasma torasemide concentrations and daily diuresis and natriuresis.
Torasemide PK was linear. After rapid absorption (Tmax 0.5–1 h), 61% of the bioavailable
torasemide was eliminated unchanged in urine. Diuresis and natriuresis observed with
torasemide were similar to the ones obtained after furosemide (daily dose-ratios: 1/20 to
1/10). The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs)
to 730 ±120mL after the first torasemide administration and up to 1150 ± 252mL
after 10 administrations at the highest dose. At higher doses (≥0.3 mg/kg/day), daily
diureses after 10 diuretic treatment-days were higher than Day 1 and variable between
dogs; in contrast, diureses remained constant over time and less variable for doses
up to 0.2 mg/kg/day. Natriuresis peaked after the first day and decreased dramatically
after the 2nd treatment-day then stabilized to a value close to baseline, except for
0.4 mg/kg/day. Urinary torasemide excretion predicted pharmacodynamics better than
plasma concentrations. The decrease in natriuresis observed was successfully modeled
using a resistance mechanism; this is likely due to a reabsorption of sodium which did not
seem however to affect the volume of urine excreted. For a daily target diuresis of 460
mL/dog/day in severe pulmonary oedema (net fluid loss 240 mL/dog/day), a computed
dose of 0.26 mg/kg/day (3.5 mg/kg/day furosemide-equivalent) was selected for clinical
studies. Due to high inter-individual variability in diureses at doses ≥0.3 mg/kg, higher
doses should be limited to 3–5 days to avoid supra-clinical effects in high responders.
Keywords: loop-diuretic, natriuresis, diuresis, urine, Non Linear Mixed Effect Model (NLME), aldosterone, PK/PD,
modeling
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INTRODUCTION
Acute congestive heart failure (CHF) in dogs originates either
from mitral valve disease or dilated cardiomyopathy (1, 2).
The prevalence of these aetiologies and long term-prognosis
vary depending on breed. The pathophysiology of CHF is the
same across all species with respect to activation of the Renin
Angiotensin Aldosterone system (RAAS) and the development
of volume overload. Loop diuretics are the cornerstone for the
management of acute and chronic decompensated heart failure
and associated cardiogenic pulmonary oedema. The goal of
loop diuretic treatment of heart failure is to achieve negative
salt and water balance for reducing pulmonary oedema (acute
decongestion) in the short term and reduce extracellular fluid
volume chronically (3). Furosemide has been used historically
for 50 years in both human and animals. Furosemide dose was
determined empirically though individual dose-titration tailored
to each dog, with doses ranging between 5 and 8mg/kg/day
for acute decongestion and 1–2 mg/kg/day for maintenance
of euvolaemia.
Torasemide is a newly licensed loop diuretic for the
treatment of congestive heart failure in dogs, with once-daily
administration. It has been licensed in human medicine since
1993, by the FDA. Torasemide and furosemide both inhibit the
activity of the Na+-K+-2Cl− symporter in the thick ascending
limb of the loop of Henle by binding to chloride binding site
of the symporter from the luminal side; hence the time-course
of urinary concentration of loop diuretic is relevant to the
activity of the drug (4). Torasemide has several advantages over
furosemide. The oral absorption of torasemide is reproducible
as its bioavailability is consistently high in fasted and fed
states, reaching 98% when fed (5), vs. 77% with furosemide.
Although torasemide is partially metabolized in non-active
metabolites, the kidney remains the major route of elimination
as 60% of torasemide is excteted in urine unchanged, vs.
around 20% with furosemide. The filtration of torasemide is
limited by its extensive binding to plasma protein in dogs
[98.4%, (6)] but is actively transported into the proximal
tubule by the organic anion transport system. After repeated
administration, diuretic resistance develops with furosemide
whereas the diuretic effect is preserved at 14 days with torasemide
(7). Finally, although torasemide is not a mineralocorticoid
receptor antagonist (8), possible indirect blockade of aldosterone
action could have beneficial antifibrotic effect through other
anti-remodeling mechanisms (indirect anti-aldosterone effect),
explaining a possible long-term survival benefit of torasemide
over furosemide in people (9).
The objective of this paper is to propose a data-driven
computation of an optimally effective dosage regimen of
torasemide for dogs with pulmonary oedema, based on
preclinical data. The analysis relied on the evaluation of
torasemide effects after repeated oral administrations of different
doses administered to healthy dogs, using two approaches: (i) first
a comparison of diuretic effect with different doses of torasemide
vs. furosemide to establish the dose ratio of torasemide vs. the
benchmark loop diuretic, then (ii) applying pharmacokinetic
(PK)/pharmacodynamic (PD) modeling methodology to justify
a range of clinical doses required to achieve a targeted
daily fluid loss. Using this approach in drug development
offers the possibility to pool data from different studies
to gain integrated information on pharmacokinetics and
pharmacodynamics (better estimation of parameters and their
individual variability due to complementary datasets) (10).
In the present study, we propose to use a population
PK/PD approach to pool torasemide data from two
randomized preclinical placebo- and furosemide-controlled
cross-over studies.
MATERIALS AND METHODS
Studies Designs and Data Collection
Two studies (Table 1 and Table S1) were performed in
accordance to European Directive 2010/63/EU on the
protection of animals used for scientific purpose (which
intrinsically enforces the 3Rs in its Article 4). Torasemide
(C16H20N4O3S. Molecular weight: 348.421 g/mol. CAS #:
56211-40-6) was administered as 2, 4, and 8mg tablets
(ISEMID R©, Ceva Santé Animale, Libourne, France)
and furosemide (C12H11ClN205S, Molecular weight:
330.75 g/mol, CAS #: 54-31-9) was administered as 10
and 40mg tablets (Dimazon R©, MSD Santé Animale,
Beaucouzé, France). All dogs were healthy based on
clinical examination by a veterinarian, hematology and
biochemistry analyses.
The first study was a randomized 5-period placebo-controlled
crossover study exploring 4 doses of torasemide (0.1, 0.2, 0.4,
and 0.8 mg/kg), administered once daily (morning) for 14 days
(Table 1). Five male Beagle dogs were included (9.3 to 11.6 kg,
1 to 2.1 year old). Tablets were administered by oral gavage
approximately 30min after the food distribution and flushedwith
water (3 to 5mL). Wash-out period was 2 weeks.
Jugular blood samples were collected twice at baseline (once
in the morning of days minus 3 and minus 1, before feed
intake), on the first day of treatment (before food intake and
at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h after treatment
administration), on Day 2 to 13 (before food intake then 2 h post
dosing) and after the last treatment of Day 14 (before food intake
then serially up to 72 h after treatment administration), as shown
in Table S1. Blood samples were collected into lithium heparin
tubes for plasma torasemide measurement and coagulation
activator tubes for plasma aldosterone measurement. Samples
were centrifuged as soon as possible at 2,500 g for 10min at 2–
8◦C, plasma/serum was aliquoted and stored frozen at −80◦C
pending analysis.
Urine was collected twice over 24 h at baseline (from Day
minus 3 to minus 2 and within 24 h prior to drug administration)
and over 24 h after treatment on Day 1 and 14 (collection periods:
0–2, 2–4, 4–6, 6–8, 8–10, 10–12, 12–24h). Dogs were encouraged
to urinate to make sure they had an empty bladder before putting
them in metabolism cages. Urine was collected at 5◦C in pre-
weighed plastic cooled containers. The containers were weighed
and urine specific gravity measured (refractometer) to calculate
urine volume. In case of urine absence in the container after
each collection interval, appropriate methods were used to collect
urine (manual expression of the bladder or catheterization if
manual expression was not successful). Catheterization was not
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TABLE 1 | List of the PK/PD studies with subject demographics, study design and torasemide doses.
Study Objectives Test product
Dosage regimen
Route of administration
N◦ of dogs
weight and
age
Study 1 Pharmacokinetic (PK) and
Pharmacodynamic (PD) of
torasemide
Repeated daily oral doses
(14 days)
Pilot study
5 periods: Placebo, torasemide 4 doses
0.1, 0.2, 0.4, and 0.8 mg/kg once a day
Oral route
Wash-out between periods: 2 weeks
5 healthy male
Beagle dogs
1–2 yo
(10.1 kg avg.)
Study 2 PK/PD + accumulation after
a single, then 3 day-break
followed by repeated oral
doses (14 days)
GLP study
9 periods: Placebo, torasemide 4 doses,
furosemide 4 doses
ISEMID® tablets (torasemide)
0.1, 0.2, 0.3, and 0.4 mg/kg once a day
Dimazon® tablets (furosemide)
1, 2, 5, and 8 mg/kg/day in 2 adm. 12 h apart
Oral route
Wash-out between periods: 2 weeks
12 healthy male
Beagle dogs
1 yo
(10.6 kg avg.)
used more than twice a day to reduce the risk of iatrogenic
infection. Urine aliquots were stored at−80◦C for determination
of urinary torasemide and sodium concentrations.
The second study was a 9-period placebo-controlled crossover
study evaluating the effects of 4 doses of torasemide and
furosemide compared to placebo, see Table 1. Another group of
12 adult male Beagle dogs (9.9–11.2 kg) and aged 15 to 19months
was enrolled.
For each period, the dogs received one of the treatments
on Day 1 and from Day 5 to 14 (but no treatment from
Day 2 to 4, in order to evaluate the pharmacokinetics and
pharmacodynamics after the first treatment day). The morning
administration occurred about 30min after the start of food
distribution. Torasemide was administered once daily (in the
morning) at 0.1, 0.2, 0.3, and 0.4mg/kg/day and furosemide twice
daily (12 h dosing interval) at 0.5, 1, 2.5, and 4 mg/kg/12 h. The
washout between periods was 2 weeks.
Blood samples were collected at baseline (once in the morning
of days minus 3 and minus 1, before feed intake), on the first
day of treatment (before food intake and at 0.25, 0.5, 0.75, 1,
1.5, 2, 4, 6, 8, 12, and 24 h after treatment administration), on
Day 12 and 13 (before food intake) and after the last treatment
of Day 14 (before food intake then serially up to 96 h after the
last administration).
Torasemide and Biochemistry Analyses
A LC-MS/MS assay for the determination of torasemide was
developed and validated in 0.1mL of dog urine. After the
addition of the internal standard torasemide-d6 and 0.2mL
of phosphate buffer solution pH5 (VWR, Fontenay-sous-Bois),
torasemide was isolated through solid phase extraction (Waters,
Milford). Chromatographic separation was achieved isocratically
on a C18 column 2.1 × 50mm, 3.5µm at 0.15 mL/min. The
mobile phase contained 0.1 formic acid in water/acetonitrile
(65:35; v/v%). Detection was accomplished using a Sciex API
2000 tandem mass spectrometer in positive ion electrospray
SRM mode. The runtime was 5.min. The standard curves, which
ranged from 20 to 120,000 ng/mL for torasemide, were fitted to a
1/x² weighted linear regressionmodel. The intra-assay precisions,
based on five levels of QC samples (LLOQ, low, medium,
high and ULOQ), were within 6.40% CV. The intra-assay
precisions, based on four levels of QC samples (low, medium,
high and ULOQ), were within 4.75% CV. At the lower limit of
quantitation (LLOQ) of 20 ng/mL for torasemide, the inter-assay
deviations of the predicted concentrations from the nominal
values were within 4.43% for torasemide. The specificity was
demonstrated: the response measured in blank samples is <20%
of the response measured at the lower limit of quantitation.
Stability of torasemide in dog urine was demonstrated for
approximately 9 months at −80◦C (see method validation data
in Table S2).
A LC-MS/MS method was developed and validated for the
quantitation of torasemide in 0.1mL of dog plasma. The method
utilized torasemide-d6 as internal standard. After the addition
of the internal standard, the samples were processed using
crash protein precipitation with methanol. Chromatographic
separation was achieved with gradient elution on a C18 column
100× 3mm, 3.5µm at 0.4 mL/min. The mobile phase contained
water, ethanol and formic acid. Detection was accomplished
using a Sciex API 3000 tandem mass spectrometer in positive
ion electrospray SRM mode. The standard curves, which ranged
from 5 to 4,000 ng/mL, were fitted to a 1/x² weighted linear
regression model. The intra-assay precisions, based on five levels
of QC samples (LLOQ, low, medium, high and ULOQ), were
within 4.88% CV and inter-assay precisions were within 9.04%
CV. At the lower limit of quantitation (LLOQ), the inter-assay
accuracy were within 1.72%. The specificity of the method was
demonstrated. The LLOQ response ratio, when compared to the
QC0 response ratio, was>5. Torasemide was stable in dog plasma
for at least 184 days at−80◦C (Table S1).
Urinary sodium was measured by a potentiometric method
(KONELAB 60). A ligand-binding assay was validated for the
quantitation of aldosterone in dog serum. The aldosterone kit
(Demeditec Diagnostics GmbH) was a solid phase enzyme-
linked immunosorbent assay (ELISA), based on the principle
of competitive binding. The microtiter wells were coated with
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a polyclonal rabbit antibody directed toward an antigenic site
of the aldosterone molecule. Endogenous aldosterone of study
samples competed with an aldosterone-horseradish peroxidase
conjugate for binding to the coated antibody. After incubation
the unbound conjugate was washed off. After addition of the
substrate solution, the intensity of color developed was invertedly
proportional to the concentration of aldosterone in the sample.
The quantification range was 10 to 1,000 pg/mL. The calibration
curve was fitted to a 4-parameter logistic regression model. The
inter-assay precision was within 35.3% CV and the intra-assay
precision was within 35.3% CV. The inter-assay accuracy was
within ± 7.3% of the nominal values. Aldosterone in dog serum
was stable for 6 h at room temperature, 2 months at −20◦C and
was also stable for three freeze-thaw cycles.
Torasemide Population Pharmacokinetic
and Pharmacodynamic Analysis
Data from the two studies were pooled; in study 1, blood
samples were collected every day with repeated administration
of torasemide, whereas study 2 focused on the first and the last
dose for the plasma samples.
The population pharmacokinetic—pharmacodynamic
analysis was performed using Nonmem R© 7.3 software (ICON,
USA). All the population PK and PD analyses were performed
with the First Order Conditional Estimation (FOCE) method.
Data generated from study 1 and 2 were pooled together and
analyzed simultaneously. In a previous target animal safety
study (in preparation for submission), dilatation of tubules and
subcapsular cysts in the renal cortex were observed at the high
torasemide dose of 0.8 mg/kg. Therefore, to avoid any bias in
the PK/PD analysis due to modification in the site of action, the
PK/PD analysis was performed without data from the 0.8 mg/kg
dosing period.
General Approach to Model Building
Model building was performed in two steps. The first step was
to identify the structural model, which is the model that best
described the data in the absence of variability from PK data or
from PD data. Once the structural models have been established
(Figure 1), the variability of the parameters was assessed for
each model.
In a population analysis, there are usually two sources of
variability: the inter-individual variability (IIV) on the one hand,
and the residual (unexplained) variability, on the other hand (11).
The typical parameters of the population were estimated
as well as the IIV (assuming a log-normal distribution). Each
parameter was modeled following the usual exponential model.
Hence, the model parameter for the ith subject (θi) is
written as:
θi = θµ ∗ EXP(ηi)
Where θi is the parameter of the i
th subject, θµ is the population
mean of the parameter in question also called typical value and
a random parameter eta (ηi), which is the deviation from the
mean for the ith subject. Eta distribution has for mean zero and
for variance ω2 (i.e., IIV of the parameter).
η ≈ N(0,ω2)
In the present analysis, a diagonal matrix formed by the variance
terms was selected (covariances were not estimated).When a log-
normal distribution of parameters assumed, the variance estimate
is in the log-domain and does not have the same magnitude as
the θ values. The following equation converts the variance to a
coefficient of variation (CV%) in the original scale (11).
CV (%) = 100×
√
exp
(
ω2
)
− 1
Parameter estimation with their associated SE as a measure of the
precision of the estimation was based on minimizing an objective
function value (OFV), using maximum likelihood estimation.
The OFV, expressed as minus twice the log of the likelihood
(-2LL), is a single number that provides an overall summary
of how closely the model predictions (given a set of parameter
values) match the data (maximum likelihood = lowest OFV
= best fit). The likelihood ratio test (LRT), was performed to
statistically compare different nested models: a reduction of at
least 10.83 (corresponding to a P< 0.001 for 1 degree of freedom)
was required to choose the more complex model.
Shrinkage of random effect toward the typical values can
occur when data are not dense enough to estimate the random
component. The shrinkage for the etas were estimated as
follows (11):
shrinkage = 1−
SD(EBEη)
ω
where ω is the estimated variability for the population and SD
is the SD of the individual values of the Empirical Bayesian
Estimates (EBE) of η. When η shrinkage are high (>30%),
plotting individual-predicted concentrations or parameters vs.
a covariate (as in diagnostic plots) may be misleading but
model comparisons on Objective Value Functions (OVF) and
population predictions are unaffected.
The estimation of IIV for certain parameters was decided
based on data profiles, precision of parameter estimates in the
structural model, η shrinkage and plausibility. The resulting
model performance was assessed by the OFV, the goodness of fits
plots (DV vs. IPRED, CWRES vs. PRED, Visual predictive check),
the plausibility of parameter estimates and their precision, and
the residual variability.
For residual variability, the residual model was multiplicative
(proportional) plus an additive model of the form:
C(t) = f (θ ,Time)× (1+ ε1)+ ε2
with two random effects, ε1 and ε2, as the multiplicative error
term (mean of 0 and a variance noted σ1) and the additive error
term (mean of 0 and a variance noted σ2), respectively.
Pharmacokinetic Modeling
The pharmacokinetic data were analyzed in accordance with
Guideline on reporting the results of population pharmacokinetic
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analyses (12). The theoretical blood sampling time points related
to the preceding administration were used except when the
difference between the actual time of collection and the planned
time of collection exceeded +/−5%. At time points in the lag-
time between time zero and the first drug concentration equal or
above Limit of Quantification (LOQ), drug concentrations below
LOQ were set to zero. Trailing concentrations below LOQ were
not used in calculations.
The simplest model tested was composed of one central
compartment with an absorption compartment. This model was
then completed with additional peripheral compartments until
the addition of a new compartment failed to significantly improve
the model. Bioavailability was estimated precisely in a previous
study (5) and used as an input in the current model (value fixed
to 0.98).
Pharmacodynamic Modeling
According to the mechanism of action, the PD modeling was
performed using the quantity of torasemide in urine (Qurine:
quantity of torasemide excreted in urine in µg per day), rather
that torasemide plasma concentrations since the sites of action of
torasemide are located in the luminal side of the loop of Henle.
PK/PD modeling of diuresis
Daily production of urine volume was used for the quantitative
analysis of the effect of torasemide on diuresis. The natural
diuresis was taken into account in the model with a baseline
value. The effect of torasemide on diuresis was modeled with a
direct response model. The effect model tested were a sigmoid-
Emax model, an Emax model, a power model and a linear model.
Diuresis model using a power model with a baseline effect
parameter was modeled as follows (Equation 1).
EDiuresis = Baseline+ slope ∗ Qurine
αTora (1)
Where, EDiuresis is the measured effect (i.e., urine volume, in
mL/day). Baseline is the urine volume produced over 24 h
without treatment. αTora is the power parameter (unitless) and
slope is the proportional factor of the effect of torasemide on
diuresis (log10 mL/µg). The unit in log10 mL/µg, so a value of
−4.11 corresponds to 10−4.11 mL/µg or 0.0000776 mL/µg. The
model performance was assessed by the objective function value,
the goodness of fits plots, the plausibility of parameter estimates
and their precision.
PK/PD modeling of natriuresis
The effect of torasemide on natriuresis could not be modeled
with direct response model due to the shape of the natriuresis
profile and to the existence of a negative feedback (see below).
Therefore, the natriuresis was modeled with an indirect response
model. The quantity of sodium (QNa, expressed in mEq) excreted
was modeled as follows (Equation 2).
dQNa
dt
= ENa (2)
Where ENa is the formation rate of sodium in urine (natriuresis,
expressed in mEq/h). The bladder was considered empty after
each urination (i.e., urine collection).
Without drug effect, the rate of change of natriuresis (in
mEq/h2) was modeled with the following equation (Equation 3).
dENa
dt
= KforNa − kabsNa ∗ ENa (3)
Where, kforNa in is the zero-order rate constant (mEq/h
2) that
increases natriuresis and kabsNa is the first-order rate constant
(expressed in h−1) that decreases natriuresis.
The baseline natriuresis at steady state in the absence of drug
effect is expressed as in Equation 4:
ENa(steady state) = Baseline =
kforNa
kabsNa
(4)
The effect of torasemide on natriuresis was fitted with four rival
models: linear, power, simple Emax and Sigmoid-Emax model. As
an example, Equation 5 represents the Sigmoid-Emax model:
ENaTora =
EmaxNa ∗ Qurine
αToraNa
EC50_apparent
αToraNa + Qurine
αToraNa
(5)
Where, EmaxNa is the maximum drug effect on natriuresis
(proportional increase, expressed in unitless dimension) and
EC50_apparent is the daily quantity of torasemide excreted in urine
(expressed in µg, as Qurine) that produces 50% of the maximal
effect and αToraNa is the Hill coefficient (slope, unitless).
Torasemide is known to increase the natriuresis therefore, the
effect was modeled as an increase of the kforNa parameter and the
equation of natriuresis became (Equation 6):
dENa
dt
= kforNa ∗ (1+ ENaTora)− kabsNa ∗ ENa (6)
A reversible resistance (proportional decrease bounded between
0 and 100%, unitless dimension) of the diuretic effect also
called “diuretic resistance” is described in the literature (13). It
corresponds to a negative feedback that limits sodium excretion
in urine. This resistance mechanism was included into the model
(Figure 1), with an indirect response model (Equation 7).
dRNa
dt
= kResON − kResOFF ∗ RNa (7)
Where, kResON is the zero-order rate constant (h
−1) for activation
of the resistance and kResOFF is the first-order rate constant (h
−1)
for the loss of resistance. No resistance seemed to be active
for low doses of diuretics and the model could not be fitted
without a resistance threshold. Consequently, the resistance was
considered activated when the effect of torasemide on rate of
sodium excretion ENaTora (untitless) was above a threshold value,
estimated as a parameter of the model, otherwise kresON was
assigned a value of 0 (only at the lowest dose).
The resistance to diuretics decreases the effect of the drug
on natriuresis and limits the sodium excretion. The effect of
the resistance was modeled as a decrease in kforNa or an
increase in KabsNa. Since kforNa was dependent on the torasemide
effect (ENaTora), the diuretic resistance could be modeled as a
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modulation in ENaTora (Equation 4) through either an increase
in EC50 (lower potency) or as a decrease in Emax (lower efficacy)
as described in Equation 8:
EMaxNa_apparent = EMax_baseline ∗ (1− RNa ) (8)
Where, EMax_baseline is the value of EMax without resistance.
Simulation of Dose-Effect Relationship
The simulation was performed with Berkeley Madonna R©
version 8.3 (University of California, USA). Simulations
of diuresis effect were conducted at different doses of
torasemide. The simulations were performed using the
population PK/PD model developed in this paper, using
the typical parameter to simulate the average effect obtained
per dose.
FIGURE 1 | Schematic illustration of the final pharmacokinetic/pharma model, linking urinary torasemide excretion to plasma torasemide concentrations and the two
pharmacodynamic submodels for diuresis and natriuresis. The effect of torasemide on diuresis was modeled with a direct response (power model). The natriuresis
was modeled with an indirect response model. A modulator inhibiting the formation rate of sodium in urine was included to model reversible resistance to Torasemide
(negative feedback loop).
FIGURE 2 | Torasemide plasma concentration-time (µg/L) curve after daily administration for 14 days at doses of 0.1, 0.2, 0.4, and 0.8 mg/kg (Study 1).
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RESULTS
Pharmacokinetic Model
The mean plasma concentration-time and urinary excretion-
time profiles of torasemide following oral administration once
a day at 0.1, 0.2, 0.4, and 0.8 mg/kg/day in dogs (Study 1) are
presented in Figure 2 (log scale) and in Figure S14, respectively.
Themean plasma concentration-time and urinary excretion-time
profiles of torasemide following single oral administration of 0.1,
0.2, 0.3, and 0.4 mg/kg/day on day 1 and subsequently between
day 5 to 14 (Study 2) are presented in Figure 3 (log scale) and
Figure 4, respectively.
A model with 2 compartments was chosen to describe the
pharmacokinetics of torasemide over a compartmental model
(OFV: −142) (Figure 1). The schematic illustration of the final
structural model is presented in 1. The estimated population
pharmacokinetic parameters of torasemide obtained with the
final model are presented in Table 2. The goodness of fits plots,
used to assess the final model performance, are presented in
Figures S1–S3 for plasma and Figures S4–S6 for urine. Body
clearance, when scaled by an average body weight of 10 kg,
was 7.7 mL/kg/h, with a urinary clearance of 4.7 mL/kg/h,
corresponding to low clearances as per (14). Urinary clearance
(Fu) was estimated as 61% of total clearance and model
analysis was not able to find a difference between doses for
this parameter.
For all doses, the accumulation ratio was not different from
unity. However, torasemide plasma AUC did not statistically
verify dose proportionality when assessed with a power model
(Y = α × AUC0−∞
β ), β was 1.26 for the single dose (90%
Confidence interval 1.17–1.35) and 1.59 (90% CI 1.30–1.88) for
the repeated dose.
Pharmacodynamic Effects: Diuresis
Torasemide and Furosemide Diuretic Profiles
The mean and SD urine volumes excreted over 24 h obtained
after first or repeated oral administrations of torasemide (0.1
to 0.4 mg/kg/day, in one daily dose) or furosemide (1 to 8
mg/kg/day, in 2 daily doses) in dogs from study 2 are presented
in Figure 5 (first vs. repeated dose diuresis) and Figure 6 (daily
diuresis for 14 days).
Following oral administrations of torasemide and furosemide,
urine volume excreted over 24 h increased with doses. This
relationship urine volume vs. dose was observed either after a
single dose or after repeated doses.
The average urine volume excreted per day was relatively
constant over time, with repeated doses of torasemide up to
0.2 mg/kg/day and with repeated doses of furosemide up to 2
mg/kg/day but kept increasing for higher doses of either drugs.
With repeated 0.3 mg/kg/day doses of torasemide, the average
volume increased from 512mL after the first administration
to 625mL after the 9th dose and 773mL after the 10th
dose. With repeated 0.4 mg/kg/day doses of torasemide, the
average urine volume increased after the 3rd dose from 638mL
after the first administration to 1,150mL after the 10th dose.
With repeated doses of furosemide at 5 mg/kg/day, the
average urine volume increased from 581mL after the first
administration to 867mL after the 10th day of administration.
With repeated dose of furosemide at 8 mg/kg/day, the average
FIGURE 3 | Torasemide plasma concentration-time curve (µg/L) after daily administration on day 1 and daily5 and 14 at doses of 0.1, 0.2, 0.3, and 0.4 mg/kg
(Study 2).
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FIGURE 4 | Torasemide urine quantity-time curve (µg) after daily administration on day 1 and daily between days 2, 5 and 14 at doses of 0.1, 0.2, 0.3, and 0.4 mg/kg
(Study 2).
TABLE 2 | Torasemide population pharmacokinetics parameters.
Parameter Unit Description Typical value
(RSE%)
Inter-Individual
variability
CV% (RSE%)
[Shrinkage]
F Bioavailability 0.98 FIX* –
ka /h Absorption constant rate 1.66 (18.7%) 126.1% (11.5%)
[49.9%]
CL L/h Total Clearance 0.077 (11%) 64.3% (16.6%)
[47.3%]
Fu Urine fraction of the total
clearance
0.611 (2.4%) 8.6% (14.7%)
[10.1%]
Vd L Volume of distribution of
the central compartment
0.145 (23.9%) –
Q L/h Clearance of transfer
between compartments
0.262 (16.8%) –
VdPER L Volume of distribution of
the peripheral
compartment
0.935 (4.6%) –
Proportional error residual in plasma (%) 18.4% (13.8%) –
Proportional error residual in urine (%) 22.5% (12.1%) –
Additive error residual in urine (µg) 3.68 µg (41%) –
*Estimated precisely in a previous study. CV, Coefficient of variation; RSE, Relative
Standard Error.
F, bioavailability (fixed from unpublished study reported in European Public Assessment
Report (5), ka, constant rate of absorption; Vd, volume of distribution of the central
compartment; Q, clearance between central and peripheral compartment; VdPER, volume
of distribution of the peripheral compartment; CL, the total body clearance and fu, urine
fraction of the total clearance.
urine volume increased after the 3rd day onwards, from
691mL after the first administration to 1,063mL after the
10th dose.
A low to moderate intra-individual variability of the diuretic
effect was observed up to 0.2 mg/kg/day torasemide (CV at
26.9 and 29.4% for 0.1 and 0.2 mg/kg/day, respectively) and
up to 2 mg/kg/day furosemide (CV at 23.9 and 24.1% for 1
and 2 mg/kg/day, respectively). Diuresis increases at higher
doses of torasemide (0.3 and 0.4 mg/kg/day, with CV at 37.9
and 43.5%, respectively) and furosemide (5 and 8 mg/kg/day,
with CV at 38.3 and 45.5%, respectively) were highly variable
among dogs.
At the end of the treatment period, the urine volume
decreased rapidly and returned to baseline in one day
for doses up to 0.2 mg/kg/day torasemide and 2 mg/kg
furosemide. For higher doses, the daily urine volume
decreased at the end of the treatment to a steady state
higher than the original baseline (220 mL/day). This was
∼370mL at 0.3 mg/kg/day and 510mL at 0.4 mg/kg/day for
torasemide and ∼450mL for both high doses furosemide.
The measurements were only continued for 2 days beyond
cessation of dosing, so the kinetic of resumption of normal
diuresis at these doses is unknown. However, the study was
conducted with a cross-over design and the baselines measured
at the beginning of each period were similar, indicating
that these higher diuresis levels returned to the original
baseline before the beginning of the next treatment period
(washout 2 weeks).
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FIGURE 5 | Mean and SD urine volumes (mL) excreted over 24 h obtained after single or daily repeated oral administrations of 0.1, 0.2, 0.3, or 0.4 mg/kg/day of
torasemide once a day or 1, 2, 5, or 8 mg/kg/day of furosemide (in 2 daily administrations) in dogs of study 2.
PK/PD Modeling of Torasemide-Induced Diuresis
A power model was chosen to describe the pharmacodynamic
diuretic effect of torasemide over the linear (OFV: −83),
simple Emax (OFV: −83), and sigmoid Emax (OFV: −1,202)
models (Figure 1). The estimated population pharmacodynamics
parameters of torasemide on diuresis obtained with the final
PD model are presented in Table 3. The goodness of fits plots,
used to assess the final model performance, are presented
in Figures S7–S9.
Pharmacodynamic Effects: Natriuresis
Torasemide and Furosemide Natriuretic Profiles
Following first oral administration of torasemide and furosemide,
the quantities of sodium excreted over 24 h increased with
dose (Figure 7). From a baseline of 16 mEq/day, torasemide
and furosemide rose natriuresis to 56.6 and 56.2 mEq/day,
with their respective maximal doses. Natriuresis decreased
dramatically after the 2nd and 3rd treatment days of study
2 and then remained stable until the end of the treatment
period (Figure 8). For doses up to 0.3 mg/kg/day of torasemide,
natriuresis decreased to a value near the baseline and for a
0.4 mg/kg/day dose, natriuresis decreased to a higher value (27
mEq/day) within 2 days after cessation of treatment. Similarly,
with low doses of furosemide (up to 2 mg/kg/day), natriuresis
decreased to values near the initial baseline values and for 8
mg/kg/day dose, natriuresis decreased to a value higher than
baseline (28 mEq/day). At the end of the treatment period, a
temporary decrease in the natriuresis below the baseline (sodium
retention) was observed in all dogs and for all doses with
both drugs.
PK/PD Modeling of Torasemide-Induced Natriuresis
The sigmoid Emax model outperformed the linear (OFV: −73),
power (OFV: −72) and simple Emax (OFV: −119) models
(Figure 1). This indirect response model related the quantity of
torasemide excreted in urine to the effect to a stimulation of
sodium loss (KforNa). The maximal effect (Emax) was 4.67 and
the quantity of torasemide excreted in urine that produces 50%
of the maximal effect EC50 was 1,080 µg of urinary torasemide
per day.
A “diuretic resistance” mechanism was modeled with an
indirect response model where torasemide urinary excretion
fractionally decreased the maximal effect Emax when ENaTora
exceeded a fractional threshold of 0.055 or 5.5%. This means
that when the rate formation of natriuresis ENaTora, exceeds
5.5% of the baseline value, the resistance will be triggered.
Practically, only the lowest dose did not reach threshold. For
modeling diuretic resistance in natriuresis, modeling loss of
efficacy (fractional reduction of Emax) outperformed decrease in
potency (fractional increase in EC50, OFV −100) or increase in
effect dissipation (increase in kabsNA, OFV−58,609).
The estimated population pharmacodynamics parameters of
torasemide on natriuresis obtained with the final PD model are
presented in Table 4. The goodness of fit plots, used to assess the
final model performance, are presented in Figures S10–S12.
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FIGURE 6 | Mean urine volumes (mL) excreted over 24 h profiles obtained after daily repeated administrations of 0.1, 0.2, 0.3, or 0.4 mg/kg/day of torasemide or 1, 2,
5, or 8 mg/kg/day of furosemide (in 2 daily administrations) in dogs of study 2.
Aldosterone
Aldosterone concentrations increased with dose (Figure 9). In
study 1 (Figure 1), peak aldosterone concentrations were reached
at 48 h and concentrations progressively came back to baseline
with the 0.1 and 0.2 mg/kg dose, whereas they stabilized around
250 ng/L and 450–500 ng/L from day 7 to 14 for doses of 0.4 and
0.8 mg/kg, respectively. After a single day administration (study
2, Figure S13), the mean serum concentration of aldosterone
increased dose-proportionally up to 24 after dosing with all the
doses of torasemide and the two higher doses of furosemide. The
peak plasma aldosterone observed at 24 h ranged from 27.3 to
141.1 ng/L for doses of 0.1 and 0.4 mg/kg/day of torasemide and
was 109.5 and 155.1 ng/L for the two higher doses of furosemide
(5 and 8 mg/kg/day). The serum concentrations then decreased
and reached the baseline level 96 h after single day administration
with each of the doses. At steady state, just before the last
administration day (day 14), serum aldosterone concentrations
were practically at baseline levels with the two lowest doses of
torasemide and furosemide. The concentrations of aldosterone
were 69 and 120 ng/L with 0.3 and 0.4 mg/kg/day doses of
torasemide and 222 to 261 ng/mL with 5 and 8 mg/kg/day
of furosemide.
Dose Determination
First, an abacus (Table 5) was designed from the observed
data at day 9 to understand the dose correspondence
between furosemide and torasemide for diuresis effect. The
Torasemide/Furosemide dose ratio for equivalent daily diuresis
was approximately 1/10 at doses up to 0.2 mg/kg of torasemide
and reached 1/20 at the highest doses. The torasemide dose-
response relationship for diuresis (24 h period) in dogs was
simulated from the PK/PD model and is presented in Figure 10.
Higher inter-individual variability was observed from doses
equal or higher than 0.3 mg/kg/day.
DISCUSSION
PK and PD of Torasemide
Torasemide was rapidly absorbed after oral administration;
with peak plasma concentrations obtained within 1 h following
administration. Absorption half-life (25min) was identical to the
one reported by Paulin et al. (15). The bioavailability value (98%
estimated from a previous unpublished study, reported in the
European Public Assessment Report (5) inputted in the model
was in line with the one estimated by Paulin et al. (91.8%).
Torasemide clearance estimate (7.7 mL/kg/h) was slightly lower
than Paulin et al. (12.4 mL/kg/h). In healthy Beagles with normal
renal function, our estimate of 61% of the dose of torasemide
eliminated unchanged in the urine differed slightly from the one
from Paulin et al. (80%) (15). Torasemide’s longer elimination
half-life (around 6 h vs. 3 h for furosemide, measured in the
present study by results not shown), combined with higher
potency and extensive urinary excretion makes it appropriate for
dosage every 24 h. As a consequence, diuresis induced given a
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TABLE 3 | Population pharmacodynamics parameters of torasemide-induced
diuresis.
Parameter Units Description Typical
Value
(RSE%)
Inter-Individual
variability
CV% (RSE%)
[Shinkage]
Baseline mL/day Volume of urine
produced over
24 h without
treatment
221 (4.0%) 13.4% (18%)
[11%]
slope log10
mL/µg
Proportional
factor of the
effect of
Torasemide on
diuresis
−4.11
(13%)
45.8% (15%)
[26%]
αTora – Power
parameter
2.05 (9%) 3.9% (36%)
[49%]
Proportional error residual (%) 43.2%
(4%)
Where, EDiuresis is the measured effect (i.e., urine volume, in mL/day).
EDiuresis = Baseline+ slope * Qurine
αTora
Baseline is the urine volume produced over 24 h without treatment. αTora is the power
parameter (unitless) and slope is the proportional factor of the effect of torasemide on
diuresis (mL/µg). The unit in log10 mL/µg, so a value of −4.11 corresponds to 10
−4.11
mL/µg or 0.0000776 mL/µg. The model performance was assessed by the objective
function value, the goodness of fits plots, the plausibility of parameter estimates and
their precision.
once a day administration of torasemide was the same as with
furosemide given at an equivalent dosage in 2 administrations.
Moreover, no accumulation occurred after 14 days, even though
PK deviates from linearity at higher doses.
Using the quantity of torasemide in urine as factor supporting
the activity provided amuch better fit thanmodeling with plasma
concentrations and was the most physiologically relevant option
as torasemide is secreted into the proximal convoluted tubule
through organic anion transporters (4). Contrary to Paulin et al.
(15), who modeled torasemide PK/PD relationship over 96 h
following a single administration and used a 5 day diuresis dataset
from another set of dogs to validate the model, the present
model pools intensely sampled PK and PD information from 17
dogs treated for 14 days with a range of doses bracketed within
clinically relevant options. Longer treatment and more intense
monitoring increase our confidence in the immediate effects and
body adaptation to torasemide treatment.
Torasemide-inducted diuresis was comparable to a previous
study (16), where dogs were administered 0.2 mg/kg torasemide
twice a day (60 and 90 mL/kg/day after day 1 and 14,
respectively). In the present study, diuresis after 10 treatment
days were higher than after a single treatment day for high
doses torasemide (≥0.3 mg/kg/day), whereas for doses up to
0.2 mg/kg/day, the daily diuresis remained constant over time.
Similar time-dependent increase was observed with doses of
furosemide ≥5 mg/kg/day. Since the quantity of torasemide
excreted in urine was constant over time, no accumulation of
torasemide could explain this increase. The increase of diuresis
over time at doses ≥0.3 mg/kg/day was highly variable between
dogs; therefore we recommend to limit the administrations at
doses higher than 0.3 mg/kg/day for a 3–5 days maximum period
to prevent an excessive diuretic effect in some dogs that respond
highly to the drug. Of note, the same increase in variability
was observed with furosemide at doses above 5 mg/kg. While
additional experiments are warranted to ascertain the clinical
relevance of this finding on the optimal furosemide dosing
regimen, this may be kept in mind while using furosemide on
clinical cases.
Natriuresis increased after the first dose after starting repeated
torasemide administration, then decreased dramatically after the
2nd and 3rd treatment days and remained constant until the
end of the treatment period. For doses up to 0.3 mg/kg/day,
natriuresis decreased to a value close to the baseline value
and for 0.4 mg/kg/day dose, natriuresis decreased to a slightly
higher value than the baseline one (27 mEq/mL). Similar profiles
were also observed with furosemide. The decrease in natriuresis
could only be modeled with inclusion of a reversible threshold-
activated resistance and was not associated with changes in
diuresis, leading to typically observed increasingly hypotonic
urine production (4). Progressive loss of natriuresis is due to a
combination of various possible mechanisms resulting in what is
called “diuretic resistance.”
Resistance to Natriuresis Induced by
Loop-Diuretics
During each treatment period, the sodium excretion was the
result of 3 mechanisms: i) the basal excretion of sodium
(sodium intake minus renal and non-renal losses), ii) the
torasemide effect and iii) the “diuretic resistance” for which the
natriuretic component was empirically captured by the model.
At the end of each treatment period, the torasemide urine
concentration decreased quickly, leading to a rapid offset of
its natriuretic effect. Due to the slower reversion of natriuretic
resistance, sodium urinary excretion briefly fell below the
original baseline the day after the last dose. The magnitude
of the negative overshoot was commensurate with the dose-
dependent intensity of natriuretic resistance for both drugs.
The sodium excretion returned to its original baseline after a
limited amount of time (around 24 h) confirming the rapid
reversibility of the mechanism of natriuretic resistance induced
by loop diuretics.
Real or apparent loop diuretic resistance can occur because
of 3 possible mechanisms in hypervolaemic human patients
(17). The most common is what is understood as rebound
sodium retention, where blockade of sodium reabsorption at
the loop of Henle leads to hypertrophy of the distal sites of
the nephron and pronounced sodium reabsorption through
increased expression of Na+/Cl− cotransporter located in the
distal convoluted tubule (18). A second mechanism is a post-
diuretic effect aiming at protection of the intravascular volume,
is likely mediated by activation of angiotensin II or sympathetic
nervous system (17). This compensatory sodium-retention effect
is exacerbated when the diuretic action wanes before the
next dose and urinary concentrations are low. More sustained
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FIGURE 7 | Mean and SD quantities of sodium (mEq/day) excreted over 24 h obtained after single or daily repeated oral administrations of 0.1, 0.2, 0.3, or 0.4
mg/kg/day of torasemide once a day or 1, 2, 5, or 8 mg/kg/day of furosemide (in 2 daily administrations) in dogs of study 2.
exposure to loop diuretics may prevent the second mechanism
and have been explored in large scales randomized trials as
the DOSE trial (19) which compared continuous infusion and
intermittent boluses in 308 patients in acute decompensated
heart failure (see infra). The last mechanism, which may occur
concomitantly with the two previous ones, is “diuretic braking”
or tolerance. It is a true loss of patient’s response to diuretic
after the first dose, depending on the degree of volume and
sodium depletion.
Jardim et al. (20) describe in details the pathophysiology
of diuretic resistance, in particular the neuro-hormonal
activation. Hyponatraemia and activation of the Renin
Angiotensin Aldosterone System (RAAS) could have led
to the observed dose-dependent aldosterone response.
RAAS could have been activated in a volume independent
pathway in the MD because of the loss of the link between
tubular chloride and inhibition of renin secretion. The
sensing is through chloride co-transport which is blocked
by torasemide/furosemide, hence activation of renin secretion
occurs very quickly following administration of either drug.
The other possible activation pathway is through volume
contraction (vascular stimulus) (13, 21). RAAS activation
leads to sodium retention through promotion of tubular
compensatory adaptation, post-diuretic sodium retention and
diuretic braking phenomenon.
What Dose Is Necessary for Efficient
Decongestion in Acute Congestive Heart
Failure?
Congestion is defined as the signs and symptoms of extracellular
fluid accumulation, instigated by an increase in left-sided cardiac
pressures (22). The question of a-priori dose finding for a
diuretic to achieve decongestion is a rare exercise and can be
approached by i) targeting sufficient reduction of circulating
blood volume or ii) matching net fluid losses empirically required
to achieve euvolaemia.
Blood volume may be increased by as much as 30% in
dogs with severe heart failure (23) and it could be tempting to
consider primary reduction in blood volume to inform diuretic
doses. However, one needs to distinguish between changes in
total blood or interstitial tissue volume (volume overload) and
changes in venous capacitance (volume misdistribution); their
contribution to congestion may differ widely between patients
(22). Miller and Mullan (24) measured total blood volume and
plasma volume (radiolabeled-albumin dilution) in 26 patients
with decompensated chronic heart disease before and after
diuretic therapy. There was substantial variability in the source
and quantity of fluid removed with respect to intravascular and
interstitial compartments. Compared to expected normal blood
volume (5.3 +/– 0.7 L), total blood volume was 39% increased
on admission (7.4 +/– 1.6 L, range 9.5 to 107% increase) and
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FIGURE 8 | Mean daily natriuresis time-profiles (mEq/day) profiles obtained after daily repeated administrations of 0.1, 0.2, 0.3, or 0.4 mg/kg/day of torasemide or 1,
2, 5, or 8 mg/kg/day of furosemide (in 2 daily administrations) in dogs of study 2.
still 30% increased on discharge (6.7 +/- 1.3 L, range 9–51%
increase). The major component of the volume loss (85%) was
derived from the interstitial space (calculated as 6.2 +/– 0.4 L)
and not the plasma (15%) and definitely precludes diuretic dose
determination based on circulating volume reduction.
On the other hand, there is a clear inverse relationship
between the immediate efficacy of decongestion (urine output
and net fluid loss) and short-term survival. In a sample of 475
patients with acute decompensated heart failure (ADHF), both
net fluid loss (sum of daily fluid intake minus total output) and
urine output following furosemide treatment were dose related
amongst other variables and correlated with 6 months mortality
(25). Mean urine output was 2.7 L after 24 h with a net fluid
loss was 1 L per 24 h, corresponding to 14.2 mL/kg/day for an
average 70 kg human patient. Response to diuretic in patients
with ADHF involves a complex and dynamic process; dose was
the strongest predictor of urine output, but only explained 50%
of the variability in diuresis, the rest of the variability being
explained by renal function, hemodynamic statues, degree of
initial volume overload and fluid intake.
Despite ubiquitous use of loop diuretics in human patients,
there is only one randomized controlled trial (Diuretic
Optimization Strategies Evaluation DOSE trial) that has
prospectively compared the effect of dosage regimen in the
treatment of acute heart failure (19). A sample of 308 patients
were randomly assigned to one treatment of the 2 × 2 factorial
design including dose (low dose 1 × vs. high dose 2.5x) and
dose intensity (repeated bolus vs. continuous infusion). Higher
doses were associated with higher diuresis and improved relief
from dyspnea and were not associated with worse clinical
outcome at 60 days. The mean 72 h-cumulated net fluid loss
were 3.6 L and 4.9 L, which correspond to average daily net
fluid losses (70 kg patient) of 17 and 23 mL/kg/day for the
low and high doses, respectively. Extrapolating to a 10.5 kg
dog with a model-estimated baseline diuresis of 220 mL/day
(Table 5), low and high dose decongestion target additional
urine volumes of 180mL (target daily diuresis = 180 + 220 =
400mL) and 240mL (target daily diuresis = 460mL) for the low
and high dose decongestion targets, respectively. Another study
(CARRESS-HF) compared outcomes between conventional
diuretic therapy and mechanical ultrafiltration (which involves
removal of iso-osmotic filtrate) in 188 patients with ADHF (26).
Aggressive diuretic titration followed a urine output-guided
protocol, targeting 3 to 5 L per day. Cumulative fluid loss were
averaging 3 L for the first 24 and remained constant until 96 h
where cumulated fluid loss was 12 L. Assuming baseline daily
diuresis of 1.4 L for a normal 70 kg person, daily additional
urinary losses during the trial were a 22.8 mL/kg/day, yielding by
extrapolation an additional 240mL diuresis for a 10.5 kg dog.
Extrapolating from the DOSE (19) and CARRESS-HF (26)
studies, the minimal dose required to reduce the congestion in
the dog would eliminate 230mL of urine in addition to the
normal diuresis (i.e., 240mL+ 220mL= 460mL). According to
our PK/PDmodeling approach, the minimal recommended dose
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TABLE 4 | Population pharmacodynamics parameters of torasemide-induced
natriuresis.
Parameter Units Description Typical
Value
(RSE%)*
Inter-Individual
variability
CV%
(RSE%) [Shinkage]
kforNa mEq/h
2 Zero-order rate constant
for production of
natriuresis
3.67
(3.65%)
19.4% (28.30%)
[29%]
kabsNa /h First-order rate constant
that decrease the
formation of natriuresis
4.99
(5.76%)
–
EmaxNa Unitless Maximum drug effect on
natriuresis
4.67
(10.53%)
62.4% (32.44%)
[1%]
EC50Na µg Quantity of torasemide
excreted in urine that
produces 50% of the
maximal effect
1080
(5.97%)
–
αToraNa – Factor of sigmoidicity 2.57
(12.50%)
–
kresOn /h Zero-order rate constant
for activation of the
resistance
0.0811
(12.94%)
–
kresOff /h First-order rate constant
for the loss of resistance
0.0894
(11.21%)
-
Threshold Unitless Threshold of activation of
resistance
0.0547
(12.31%)
–
Proportional error residual (%) 30.5%
(7.69%)
–
ENa is the formation rate of sodium in urine (natriuresis, expressed in mEq/h), kforNa is the
zero-order rate constant (mEq/h2 ) that increase the natriuresis and kabsNa is the first-order
rate constant (expressed in h−1) that decrease the natriuresis. The effect of torasemide on
natriuresis best fitted a sigmoid-Emax model, where, EmaxNa is the maximum drug effect
on natriuresis (unitless) and EC50_apparent is the daily quantity of torasemide excreted in
urine (expressed in µg, as Qurine) that produces 50% of the maximal effect and αToraNa
is the Hill coefficient (slope, unitless). Torasemide is known to increase the natriuresis
therefore, the effect was modeled as a fractional increase of the kforNa parameter. kResON
is the zero-order rate constant (h−1 ) for activation of the resistance and kResOFF is the first-
order rate constant (h−1 ) for the loss of resistance. The resistance was active when the
effect of torasemide on rate of sodium excretion ENaTora (untitless) was above a threshold
parameter estimated by the model (otherwise kresON = 0). The effect of the resistance
was modeled as a decrease in kforNa. Since kforNa was dependent of the torasemide
effect (ENaTora), the diuretic resistance could best be modeled as a modulation in ENaTora
(Equation 4) through a decrease in Emax (lower efficacy).
*RSE: Relative Standard Error.
TABLE 5 | Corresponding doses of furosemide and torasemide for diuresis effect.
Furosemide Dose (mg/kg/day) 0 1 2 5 8
Diuresis obtained at D9 (mL/day) 210 212 365 867 1,063
Torasemide Dose (mg/kg/day) 0 0.1 0.2 0.3 0.4
Diuresis obtained at D9 (mL/day) 210 220 403 773 1,150
to treat moderate to severe pulmonary oedema associated with
congestive heart failure due to degenerative mitral valve disease
in dog would be 0.26 mg/kg/day (3.5 mg/kg/day furosemide
equivalent),. One limitation is that the studies were carried out
in healthy dogs. Torasemide oral bioavailabiltiy may not be that
high in human patients and dogs due to gastrointestinal oedema,
gastroparesis, and delayed gastric emptying (17), or the possibly
lowered of distribution of diuretic to the nephron lumen with
a cardiorenal syndrome type 1 (decompensated heart failure
leading to renal hypoperfusion).
Dose for Milder Congestion and
Maintenance Dose After Decongestion
Excess of fluid volume from canine experimental models of mild
pulmonary oedema induced chemically with either oleic acid (27)
or acetylene (28) was estimated to an average of 64mL. According
to the PK/PD model (Figure 10), the dose of torasemide that
corresponds to the sum of baseline diuresis and excess water in
these mild induced oedemas (220 + 64 = 284 mL/day) would
be 0.13 mg/kg/day. One persistent problem with treating human
patients and dogs who recover from congestion with volume
overload, is knowing when euvolaemia is reached and diuretic
dose should be reduced. The ideal maintenance dose to maintain
sustained decongestion would be one that achieves excretion
of isotonic urine with modest diuresis driven by torasemide
urinary excretion that are below the threshold of activation of
natriuresis resistance and neuro-hormonal activation. A dose of
torasemide of 0.1 mg/kg/day does not activate an aldosterone
response lasting more than 5 days, but achieves a diuretic and
natriuretic effect only slightly above baseline in healthy dogs.
A dose between 0.1 and 0.2 mg/kg/day (furosemide equivalent
to 1–2 mg/kg/day) may be evaluated in a clinical field trial as
an effective dose for milder congestion and chronic control of
extracellular fluid volume.
One limitation of the study is that we were not successful
in implementing a systems pharmacology approach, where
natriuresis, diuresis, aldosterone, as well as variables which were
measured in these studies but not reported in the present paper
(kaliuresis and GFR) and PK would be included in the same
model. It was however impossible due to the accumulation
of small bias, like relying on spontaneous micturition. Urine
was collected by physiologic urination, to avoid any additional
stress or pain that could occur with catheterization. However,
physiologic urination does not directly measure the urine
formation by the kidney in the bladder but the urine formation
between two consecutive urinations. Therefore, the urine data
would be dependent of the interval of urination and could bias
the results, especially when the urine collections are close (study
1). In order to avoid any bias, urine was analyzed over 24 h
periods, so for each day, the urine volumes and the quantity of
urinary sodium and torasemide were summed over 24 h periods.
The mechanism whereby urine volume, but not sodium
excretion, increases at higher doses over the 14 day dosing
period, leading to dissociation between sodium and water
excretion is difficult to explain. A washout of the medullary
interstitial sodium gradient could have led to inability
to concentrate the urine. However, it is unclear (i) why
water excretion continues to increase over time with either
diuretics, (ii) what the therapeutic consequences are and
(iii) what underlies the individual variability between dogs.
The measurement of plasma ADH concentration, water
balance and plasma osmolality over this dosing period
would be interesting in future studies to understand this
phenomenon better.
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FIGURE 9 | Mean serum aldosterone concentration (ng/L) time-profiles profiles obtained before and 2 h after daily repeated administrations of 0.1, 0.2, 0.3, or 0.4
mg/kg/day of torasemide in dogs of study 1.
FIGURE 10 | Dose response relationship between diuresis (mL/day period) and doses of torasemide in dogs (mg/kg/day) as computer from the PK/PD model. The
variability observed with real data is represented with error bars (Doses with high variability in effect plotted in red).
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CONCLUSION
Using the quantity of torasemide excreted in urine provided a
much better prediction of torasemide pharmacodynamics than
the plasma concentration-time course. A once-daily dosage
regimen is supported by pooled PK/PD analysis of 2 preclinical
studies with daily administration extending over 14 days. The
dose ratio torasemide/furosemide decreased with dose (1/10 at
doses ≤0.2 mg/kg/day torasemide to 1/20 at the highest dose of
0.4 mg/kg). For a daily target diuresis of 460mL (decongestion
of moderate to severe acute pulmonary oedema), a minimal
dose of 0.26 mg/kg/day (3.5 mg/kg/day furosemide equivalent)
is proposed for evaluation into clinical phases. Due to the high
inter-individual variability in responses at doses ≥ 0.3 mg/kg,
higher doses should be used for a limited period of time to
prevent too high an excessive diuretic effect in some dogs that
respond highly to the drug. Subsequently, a dose range of 0.1
to 0.2 mg/kg is proposed for mild pulmonary oedema or for
long-term control of extracellular fluid volume. PK-PDmodeling
of preclinical data substantially de-risked dose finding; however
the dose prediction capability of the model is directly linked to
the reliability of the preclinical results and should be confirmed
through pivotal clinical studies.
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